Trial · NCT03486899
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 | BMS-986036 10 mg | 30.6 | 0.88 to 8.52 | Percentage of Participants | |
| The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 | BMS-986036 20 mg | 24.0 | 0.61 to 6.27 | Percentage of Participants | |
| The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 | BMS-986036 40 mg | 26.5 | 0.71 to 7.10 | Percentage of Participants | |
| The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 | Placebo | 14.3 | NA to NA | Percentage of Participants | |
| The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24 | BMS-986036 10 mg | 16.3 | Percentage of Participants | ||
| The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24 | BMS-986036 20 mg | 14.0 | Percentage of Participants | ||
| The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24 | BMS-986036 40 mg | 20.4 | Percentage of Participants | ||
| The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24 | Placebo | 8.2 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24 | BMS-986036 10 mg | 22.4 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24 | BMS-986036 20 mg | 16.0 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24 | BMS-986036 40 mg | 26.5 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24 | Placebo | 12.2 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24 | BMS-986036 10 mg | 42.9 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24 | BMS-986036 20 mg | 53.5 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24 | BMS-986036 40 mg | 55.8 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24 | Placebo | 65.9 | Percentage of Participants | ||
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24 | BMS-986036 10 mg | 8.2 | Percentage Participants | ||
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24 | BMS-986036 20 mg | 4.0 | Percentage Participants | ||
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24 | BMS-986036 40 mg | 2.0 | Percentage Participants | ||
| The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24 | Placebo | 6.1 | Percentage Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03486899/results